CIK 0001517022 · Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208756903
- Phone
- 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- 424B5 Offering Prospectus
- 8-K Event Exit or restructuring costs · Other events
- 8-K Event Other events
- CT ORDER Other Confidential Order
- 4 Open-market sale CEO and President sold 79,026 shares at an average $2.17 ($171,143)
- 4 Open-market sale SVP, Chief Medical Officer sold 15,056 shares at an average $2.16 ($32,564)
- 4 Open-market sale SVP, Chief Accounting Officer sold 3,946 shares at $2.15 ($8,503)
- 4 Open-market sale SVP, Chief Operating Officer sold 21,533 shares at an average $2.17 ($46,637)
- 4 Open-market sale SVP, CCO sold 13,184 shares at an average $2.16 ($28,515)
- 4 Open-market sale SVP, Chief Legal Officer sold 21,062 shares at an average $2.17 ($45,615)
- 4 Open-market sale SVP, CFO and Treasurer sold 8,203 shares at an average $2.16 ($17,689)
- POS AM Other Post-effective Amendment for Registration Statement
- 10-K Report Annual Report
- POSASR Other POSASR
- 8-K Event Results of operations
- 8-K Event Material agreement · Unregistered share sale · Regulation FD disclosure
- 4/A Other acquisition CEO and President acquired 1,248 shares (other)
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
Page 16 of 45 · 886 filings